Related pages Drug Information Summaries Approval Process for New Cancer Treatments Access to Investigational Drugs: Q & A

This page contains brief information about dexrazoxane hydrochloride and a collection of links to more information from the National Cancer Institute (NCI) and the Food and Drug Administration (FDA).

US Brand Name(s):		Totect
		Zinecard
FDA Approved:		Yes

Dexrazoxane hydrochloride is approved by the Food and Drug Administration (FDA) to treat severe side effects caused by certain types of chemotherapy. It is used to treat the following:

• Extravasation caused by intravenous anthracyclines. Extravasation occurs when injected drugs leak out of the vein, into surrounding tissue. This can cause redness, pain, and swelling, and may damage the tissue. This use is approved for the Totect brand of dexrazoxane hydrochloride.
• Cardiac (heart) side effects caused by doxorubicin in women being treated for metastatic breast cancer. Dexrazoxane hydrochloride helps make the side effects happen less often and makes them less severe when they do occur. It is used only in women who have already received high doses of doxorubicin and continue to be treated with it. This use is approved for the Zinecard brand of dexrazoxane hydrochloride.

FDA Approval for Dexrazoxane Hydrochloride - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trial Results: Heart Risks of Doxorubicin Higher Than Previously Reported (05/28/2003) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trials for Dexrazoxane Hydrochloride - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.

Back to Top